Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Novo Nordisk A/S stock

Learn how to easily invest in Novo Nordisk A/S stock.

Novo Nordisk A/S is a biotechnology business based in the US. Novo Nordisk A/S shares (NVO) are listed on the NYSE and all prices are listed in US Dollars. Novo Nordisk A/S employs 59,337 staff and has a trailing 12-month revenue of around $201.3 billion.

How to buy Novo Nordisk A/S stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – NVO. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Promoted for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 in stock when you fund a new account within 30 days

Promoted for social trading

Finder Award


  • Easy to use platform with $0 stock trading & no annual fees
  • Social trading allows you to copy popular portfolios
  • FINDER EXCLUSIVE: Guaranteed $15 bonus when you sign up and deposit $100

Promoted for active trading


  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+

Novo Nordisk A/S stock price (NYSE: NVO)

Use our graph to track the performance of NVO stocks over time.

Novo Nordisk A/S shares at a glance

Information last updated 2023-09-19.
Latest market close$91.30
52-week range$93.82 - $201.76
50-day moving average $176.81
200-day moving average $157.37
Wall St. target price$154.71
PE ratio 43.6005
Dividend yield $7.075 (1.08%)
Earnings per share (TTM) $4.28

Buy Novo Nordisk A/S stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 7 of 7
Name Product Ratings Available asset types Minimum deposit Signup bonus
SoFi Invest
Finder Rating: 4.6 / 5: ★★★★★

Finder Award
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000 in stock
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Finder Rating: 4.2 / 5: ★★★★★

Finder Award
Stocks, Options, ETFs, Cryptocurrency
FINDER EXCLUSIVE: Get a guaranteed $15 bonus
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Finder Rating: 4.1 / 5: ★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures
Get $100 - $2,000
when you you open and fund an account with $5,000 to $100,000+
Highly commended for Best Derivatives Trading Platform award.
Finder Rating: 4 / 5: ★★★★★
Stocks, ETFs, Cryptocurrency, Art, Treasury Bills, Collectibles
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
2.5% fee applies to all alternative asset transactions.
Finder Rating: 4.2 / 5: ★★★★★
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4.9% interest on uninvested cash in your account with Robinhood Gold.
JPMorgan Self-Directed Investing
Finder Rating: 4 / 5: ★★★★★
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs, Treasury Bills
Get $50 - $700
when you open and fund an account with $5,000 - $250,000+
Pay no commissions on stocks, ETFs, mutual funds and options.
Finder Rating: 4 / 5: ★★★★★
Stocks, ETFs
Wealthfront builds a free financial plan for the life you want and automate your investments at a low cost.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Is it a good time to buy Novo Nordisk A/S stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Novo Nordisk A/S price performance over time

Historical closes compared with the close of $91.3 from 2023-09-22

1 week (2023-09-18) -51.07%
1 month (2023-08-25) -51.03%
3 months (2023-06-23) -42.60%
6 months (2023-03-24) -40.23%
1 year (2022-09-23) -6.77%
2 years (2021-09-24) -9.33%
3 years (2020-09-25) 34.82%
5 years (2018-09-25) 102.22%

Is Novo Nordisk A/S stock undervalued or overvalued?

Valuing Novo Nordisk A/S stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Novo Nordisk A/S's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Novo Nordisk A/S financials

Revenue TTM $201.3 billion
Operating margin TTM 43.2%
Gross profit TTM $148.5 billion
Return on assets TTM 21.76%
Return on equity TTM 81.54%
Profit margin 33.4%
Book value $2.52
Market Capitalization $834.9 billion

TTM: trailing 12 months

Novo Nordisk A/S share dividends


Dividend payout ratio: 5.34% of net profits

Recently Novo Nordisk A/S has paid out, on average, around 5.34% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.08% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Novo Nordisk A/S shareholders could enjoy a 1.08% return on their shares, in the form of dividend payments. In Novo Nordisk A/S's case, that would currently equate to about $7.075 per share.

While Novo Nordisk A/S's payout ratio might seem low, this can signify that Novo Nordisk A/S is investing more in its future growth.

Novo Nordisk A/S's most recent dividend payout was on 28 August 2023. The latest dividend was paid out to all shareholders who bought their shares by 17 August 2023 (the "ex-dividend date").

Have Novo Nordisk A/S's shares ever split?

Novo Nordisk A/S's shares were split on a 2:1 basis on 19 September 2023. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Novo Nordisk A/S shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Novo Nordisk A/S shares which in turn could have impacted Novo Nordisk A/S's share price.

Novo Nordisk A/S share price volatility

Over the last 12 months, Novo Nordisk A/S's shares have ranged in value from as little as $93.8191 up to $201.76. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Novo Nordisk A/S's is 0.2421. This would suggest that Novo Nordisk A/S's shares are less volatile than average (for this exchange).

Novo Nordisk A/S overview

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc. ; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Frequently asked questions

What percentage of Novo Nordisk A/S is owned by insiders or institutions?
Currently 0.007% of Novo Nordisk A/S shares are held by insiders and 8.223% by institutions.
How many people work for Novo Nordisk A/S?
Latest data suggests 59,337 work at Novo Nordisk A/S.
When does the fiscal year end for Novo Nordisk A/S?
Novo Nordisk A/S's fiscal year ends in December.
Where is Novo Nordisk A/S based?
Novo Nordisk A/S's address is: Novo Allé 1, Bagsvaerd, Denmark, 2880
What is Novo Nordisk A/S's ISIN number?
Novo Nordisk A/S's international securities identification number is: US6701002056
What is Novo Nordisk A/S's CUSIP number?
Novo Nordisk A/S's Committee on Uniform Securities Identification Procedures number is: 670100205

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site